Skip to main content

BRAF Archives

Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Read more


“Idling” cancer cells may return

Apr. 11, 2018—Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

Read more


PET imaging to predict tumor response

Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

Read more


Investigators find clues to melanoma treatment resistance

Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

Read more


Combined drug therapy may delay melanoma progression

Oct. 25, 2012—Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.

Read more


Study finds mutation in melanoma sensitive to drug

Jul. 26, 2012—An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

Read more


New drug mutes more melanomas

Apr. 26, 2012—An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more